Exacerbation Frequency, COPD Symptoms, and Health-Related Quality of Life of COPD Patients According to Post-Bronchodilator FEV₁ – A Post-hoc Analysis of Pooled Data from Two Cross-Sectional Studies

Chee-Shee Chai (✉ cschai@unimas.my)

University Malaysia Sarawak

Diana-Leh-Ching Ng

University Malaysia Sarawak

Sumastika Bt Mos

University Malaysia Sarawak

Muhammad Amin B Ibrahim

University Technology MARA

Seng-Beng Tan

University of Malaya

Yong-Kek Pang

University of Malaya

Chong-Kin Liam

University of Malaya

Research Article

Keywords: Chronic obstructive pulmonary disease (COPD), forced expiratory volume in one second (FEV₁), exacerbation, modified Medical Research Council (mMRC), COPD Assessment Test (CAT), St George's Respiratory Questionnaire for COPD (SGRQ-c)

Posted Date: March 8th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1417365/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background:

This study aimed to compare and correlate the post-bronchodilator forced expiratory volume in one second (PB-FEV₁), exacerbation frequency, and scores of modified Medical Research Council (mMRC), COPD Assessment Tool (CAT), and St George's Respiratory Questionnaire for COPD (SGRQ-c) of COPD patients.

Methods:

This was a post-hoc analysis of pooled data from two cross-sectional studies conducted from 1st June 2017 to 31st May 2018 at the respiratory clinic of University of Malaya Medical Center, and from 23rd January 2018 to 22nd January 2019 at the outpatient clinics of the Serian Divisional Hospital and Bau District Hospital in Malaysia, respectively. The parameters measured included PB-FEV₁, exacerbation frequency, mMRC, CAT, and SGRQ-c. Descriptive, association and correlation statistics were used.

Results:

Of a total of 374 patients, the PB-FEV₁ predicted was < 30% in 85 (22.7%), 30 – 49% in 142 (38.0%), 50 – 79% in 111 (29.7%), and ≥ 80% in 36 (9.6%) patients. Patients with PB-FEV₁ < 30% predicted had significantly more COPD exacerbations than those with PB-FEV₁ 30 – 49% predicted ($p < 0.001$), 50 – 79% predicted ($p < 0.001$), and ≥ 80% predicted ($p = 0.002$). The scores of mMRC, CAT and SGRQ-c were not significantly higher in patients with more severe airflow limitation based on PB-FEV₁ ($p = 0.121 - 0.271$).

The PB-FEV₁ predicted had significant small negative correlations with exacerbation frequency ($r = -0.182$, $p < 0.001$), mMRC ($r = -0.121$, $p = 0.020$), and SGRQ-c scores ($r = -0.114$, $p = 0.028$). There was a moderate positive correlation between COPD exacerbation frequency and scores of mMRC, CAT, and SGRQ-c ($r = 0.407 - 0.482$, all $p < 0.001$). There were significant strong positive correlations between mMRC score with CAT ($r = 0.727$) and SGRQ-c scores ($r = 0.847$), and CAT score with SGRQ-c score ($r = 0.851$) (all $p < 0.001$).

Conclusions:

In COPD patients, different severity of airflow limitation was not associated with significant differences in the dyspnea symptom and HRQOL. Exacerbation was significantly more frequent in patients with very severe airflow limitation only. The correlation between airflow limitation with exacerbation, dyspnea symptom, and HRQOL was weak.

Background

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable airway disease characterized by persistent respiratory symptoms and airflow limitation caused by prolonged exposure to noxious particles or gases.(1) The estimated global prevalence of COPD is 13.1% with a continent-based prevalence of 12.4% in Europe, 13.2% in the Americas, 13.5% in Asia, 11.6% in Oceania, and 13.9% in Africa.(2) Worldwide, COPD is currently the fourth leading cause of mortality resulting in 3.2 million deaths annually and the second leading cause of disease burden accounting for 63.9 million disability-adjusted life-years.(3)

Forced expiratory volume in one second (FEV_1), exacerbation, dyspnea symptom, and health-related quality of life (HRQOL) are the common parameters used in the classification of COPD. FEV_1 measurement is essential in estimating the severity of airflow limitation in asthma and COPD. It is widely used by physicians for the diagnosis, staging, treatment monitoring, and determining the prognosis of COPD patients.(4) FEV_1 measurement is simple, quick, objective, reproducible, consistent, and with a well-established reference range.(5) Exacerbation frequency is a strong predictor of decline in lung function, reduced exercise tolerance, poor quality of life, and higher mortality.(6, 7) Dyspnea, the commonest symptom experienced by COPD patients, is associated with decreased physical activity, reduced HRQOL, and increased mortality.(8) HRQOL is defined as an individual's happiness or satisfaction towards his or her life which is affected by physical, mental, emotional, and social health.(9) A poor HRQOL is associated with dyspnea symptom, physical impairment, mental health problems, hospital admission, and mortality.(10, 11) For COPD, modified Medical Research Council (mMRC) is the recommended assessment tool for dyspnea symptom while HRQOL can be measured by using St George's Respiratory Questionnaire for COPD (SGRQ-c) or the abbreviated COPD Assessment Test (CAT).

In real-world practice, the parameters and assessment tools used to classify COPD are not without limitations. To date, there is no recommendation to perform spirometry regularly during the routine follow-up of COPD patients. Recall of exacerbation frequency is subjected to the patients' memory. Thresholds for patients presenting to the healthcare facility during a worsening of respiratory symptoms are different. Moreover, the threshold for healthcare workers to initiate steroid/antibiotic or admit patients to the hospital can also differ. Hospital admission may be dependent on bed availability. mMRC, CAT, and SGRQ-c are very subjective methods of assessment, as different people may comprehend their symptoms, activities, and disease impacts differently. These parameters are also dynamic and mMRC, CAT, or SGRQ-c scores can vary over time.

Therefore, we decided to conduct this analysis to look into the FEV_1 , exacerbation frequency, dyspnea symptom, and HRQOL of Malaysian COPD patients. The primary objective of this analysis was to compare the exacerbation frequency, and the scores of mMRC, CAT, and SGRQ-c of COPD patients according to the post-bronchodilator forced expiratory volume in one second (PB- FEV_1). The score of each component of SGRQ-c based on PB- FEV_1 was also analyzed. The correlation between PB- FEV_1 , exacerbation frequency, and the scores of mMRC, CAT, and SGRQ-c was the secondary objective.

Methods

Study Design and Patients:

This is a post-hoc analysis of pooled data from two cross-sectional studies that we previously conducted in Malaysia, the results of which had been published separately.(12, 13) The first study involving 189 patients was conducted from 1st June 2017 to 31st May 2018 at the respiratory clinic of the University of Malaya Medical Center (UMMC), a tertiary teaching hospital located in Kuala Lumpur.(12) The second study involving 185 patients was conducted from 23rd January 2018 to 22nd January 2019 at the outpatient clinics of the Serian Divisional Hospital and Bau District Hospital, both of which were primary healthcare centers in the southern part of the state of Sarawak.(13) Both studies aimed to compare the HRQOL of patients with stable COPD according to their clinical phenotypes.

The inclusion criterion of the first study was patients aged 40 years and above with the ratio of PB-FEV₁ to post-bronchodilator forced vital capacity (PB-FVC) of < 0.7; while the inclusion criterion for the second study was patients aged 35 years and above with the ratio of PB-FEV₁ to PB-FVC in six seconds (PB-FVC₆) of < 0.7. Otherwise, both studies had similar exclusion criteria which included patients with clinical or radiological diagnoses of other chronic lung diseases (such as bronchiectasis and interstitial lung disease), active tuberculosis, and lung tumors. The sample size was calculated based on the formula for ANCOVA, in which alpha was 0.05, power was 0.9, the number of the group was 4, and the mean value referred to the exacerbation frequency. A minimum of 52 subjects were required in each group, therefore the estimated minimum sample size was 208 patients. Written informed consent for the studies and publication was obtained from all participating patients. The studies were conducted in accordance with the Declaration of Helsinki. Ethics approval was obtained from the Medical Research and Ethics Committee of the UMMC (MECID. No 2017814-5496) for the first study and from the National Medical Research Registry of Malaysia (NMRR-17-2549-38621) for the second study.

Procedure:

In both studies, eligible patients were consecutively identified from the respective clinics. Spirometry was performed according to the American Thoracic Society and European Respiratory Society guidelines. Patient demographic data and clinical characteristics were obtained by face-to-face interviews and from the case notes. Demographic data included age, gender, ethnicity, smoking status, smoking quantity, and history of biomass smoke exposure. Clinical characteristics included the number of COPD exacerbations over the past one year and dyspnea symptom according to mMRC.

PB-FEV₁ was expressed in percent of predicted value based on the patients' age, gender, ethnicity, and height. Patients were divided into four groups according to the severity of airflow limitation based on PB-FEV₁: < 30% predicted (very severe); 30–49% predicted (severe); 50–79% predicted (moderate); and ≥ 80% predicted (mild).(1) The ethnic composition of Malaysians includes Malay, Chinese, Indian, and others (such as natives). A never smoker was defined as an individual who smoked < 100 cigarettes in a lifetime; while former or current smokers were individuals who had smoked ≥ 100 cigarettes in a lifetime.

(14) An former smoker was one who had quit smoking for more than a year at the time of interview. Smoking quantity was calculated in pack-year (number of cigarettes smoked per day/20 x number of years smoking). Exposure to biomass smoke was defined as ever exposure to smoke from the burning of wood, crop, or charcoal for ≥ 100 hours per year.(15)

An exacerbation of COPD was defined as acute worsening of the patient's condition beyond normal day-to-day variation and may warrant additional treatment.(16) Only moderate and/or severe exacerbations over the past one year before the interview that predicted the risk of future exacerbations were taken into account. A moderate exacerbation was one that required outpatient treatment with corticosteroids and/or antibiotics while a severe exacerbation was one that warranted hospitalization.(17) mMRC score was 0 if dyspnea was present only on strenuous activity, 1 when dyspnea was experienced when walking uphill, 2 when dyspnea led to walking slower than people of the same age, 3 when dyspnea led to stop for breath after walking ≤ 100 meters on level ground, and 4 when dyspnoeic during dressing or undressing or being housebound because of dyspnea.(1) Low symptom level referred to a mMRC score of 0–1 while high symptom level referred to a mMRC score of 2–4.

Patients were instructed to answer the CAT and SGRQ-c questionnaires independently to assess their HRQOL. These questionnaires were available in the original English version or validated Malay and Chinese versions. The CAT questionnaire consisted of eight items: CAT 1 – cough; CAT 2 – sputum; CAT 3 – chest tightness; CAT 4 – dyspnea; CAT 5 – activity limitation; CAT 6 – confidence to leave home; CAT 7 – sleep; and CAT 8 – energy.(18) The score of each item ranged from 0 to 5. The total score of CAT ranged from 0 to 40, with normal individuals having a total score of ≤ 6 . The SGRQ-c questionnaire assessed of three components: symptoms (questions 1–7); activity (questions 9 and 12); and impacts (questions 8, 10, 11, 13, and 14).(19) The total score and score of each component of SGRQ-c ranged from 0 to 100%. The SGRQ-c score for normal individuals was $\leq 6\%$ for total; $\leq 12\%$ for symptoms; $\leq 9\%$ for activity; and $\leq 2\%$ for impacts.(20) For both questionnaires, higher scores indicated a poorer HRQOL.

Statistical analysis

Categorical variables were expressed as percentages while continuous variables were expressed as mean $\pm$ standard deviation (SD) or median with interquartile range. The difference between groups for the categorical variables was compared using the chi-squared test, with post-hoc analysis taking adjusted standardized residual of > 2 as significant. The difference between more than two groups for the continuous variables was compared using the one-way ANOVA test or Kruskal-Wallis H test. The post-hoc analysis for the former was the Tukey test and for the latter was Dunn's procedure with Bonferroni adjustment. The correlation of continuous variables was calculated using Pearson or Spearman correlation test followed by linear regression test. The correlation coefficient (r) was defined as small or weak (0.10–0.29); medium (0.30–0.49); and large or strong (≥ 0.50). A 2-sided p-value of less than 0.05 was considered significant. Statistical analyses were performed using Statistical Package for the Social Sciences (SPSS for Windows version 25.0, SPSS Inc, Chicago, IL, USA).

Results

Demographic and clinical characteristics

A total of 374 patients were included in the analysis (Fig. 1). Their demographic and clinical characteristics are shown in Table 1. The overall mean PB-FEV₁ was $47.5 \pm 21.3\%$ predicted. The PB-FEV₁ was < 30% predicted in 85 patients (22.7%), 30–49% predicted in 142 patients (38.0%), 50–79% predicted in 111 patients (29.7%), and $\geq 80\%$ predicted in 36 patients (9.6%). The proportion of patients with a history of biomass smoke exposure was significantly higher in those with PB-FEV₁ < 30% predicted (48.2%) compared to those with less severe airflow limitation [(PB-FEV₁ 30–49% (31.7%), PB-FEV₁ 50–79% (35.1%), and PB-FEV₁ $\geq 80\%$ (19.4%), $p = 0.012$]. Otherwise, the age, gender, ethnicity, smoking status, and smoking quantity of the patients were not significantly different across the different categories of severity of airflow limitation based on PB-FEV₁.

Table 1

Demographic and clinical characteristics of COPD patients according to the severity of airflow limitation based on PB-FEV₁

Characteristic	All COPD patients, N = 374	Severity of airflow limitation based on PB-FEV ₁ (% predicted)				p-value
		< 30%	30–49%	50–79%	≥ 80%	
		Number of COPD patients (% of total COPD patients)				
		85 (22.7)	142 (38.0)	111 (29.7)	36 (9.6)	
Age (mean ± SD, 95% CI), years	67.3 ± 11.8; 66.1–68.5	65.7 ± 10.5; 63.4–67.9	67.7 ± 11.4; 65.8–69.6	67.2 ± 12.4; 64.9–69.5	70.0 ± 13.7; 65.1–74.4	0.345
Gender (n, %)	317 (84.8)	77 (90.6)	120 (84.5)	90 (81.1)	30 (83.3)	0.326
Male						
Female	57 (15.2)	8 (9.4)	22 (15.5)	21 (18.9)	6 (16.7)	
Ethnicity (n, %)	104 (27.8)	24 (28.2)	42 (29.6)	27 (24.3)	11 (30.6)	0.283
Malay						
Chinese	104 (27.8)	18 (21.2)	37 (26.1)	33 (29.7)	16 (44.4)	
Indian	31 (8.3)	6 (7.1)	14 (9.9)	11 (9.9)	0	
Others	135 (36.1)	37 (43.5)	49 (34.5)	40 (36.0)	9 (25.0)	
Smoking status (n, %)	69 (18.4)	13 (15.3)	27 (19.0)	22 (19.8)	7 (19.4)	0.422
Never smoker	201 (53.7)	45 (52.9)	78 (54.9)	54 (48.6)	24 (66.7)	
Former smoker						
Current smoker	104 (27.8)	27 (31.8)	37 (26.1)	35 (31.5)	5 (13.9)	
Smoking quantity (mean ± SD, 95% CI), pack-years	30.2 ± 27.6; 27.4–33.0	27.1 ± 22.3; 22.3–31.9	30.5 ± 29.5; 25.6–35.3	32.6 ± 29.3; 27.1–38.1	28.4 ± 25.6; 19.8–37.1	0.559

Abbreviations: COPD, chronic obstructive pulmonary disease; PB-FEV₁, post-bronchodilator forced expiratory volume in one second;

mMRC, modified Medical Research Council; SD, standard deviation; CI, confidence interval.

Characteristic	All COPD patients, N = 374	Severity of airflow limitation based on PB-FEV ₁ (% predicted)				p-value
		< 30%	30–49%	50–79%	≥ 80%	
		Number of COPD patients (% of total COPD patients)				
		85 (22.7)	142 (38.0)	111 (29.7)	36 (9.6)	
Biomass smoke exposure (n, %)	242 (64.7)	44 (51.8)	97 (68.3)	72 (64.9)	29 (80.6)	0.012
No	132 (35.3)	41 (48.2)	45 (31.7)	39 (35.1)	7 (19.4)	
Yes						
Frequency of COPD exacerbation in the past one year (mean ± SD, 95% CI)	2.2 ± 4.2; 1.7–2.6	4.0 ± 7.0; 2.5–5.5	1.8 ± 2.9; 1.3–2.2	1.6 ± 2.7; 1.1–2.1	1.1 ± 1.8; 0.5–1.8	< 0.001
All exacerbations	1.4 ± 3.1;	3.0 ± 5.5;	1.0 ± 1.8;	1.0 ± 1.8;	0.7 ± 1.1;	< 0.001
Moderate	1.1–1.7	1.8–4.2	0.7–1.3	0.6–1.3	0.3–1.1	0.106
Severe	0.8 ± 1.5; 0.6–0.9	1.1 ± 2.0; 0.6–1.5	0.8 ± 1.4; 0.6–1.0	0.6 ± 1.3; 0.4–0.9	0.5 ± 0.8; 0.2–0.8	
mMRC score (n, %)	181 (48.4)	37 (43.5)	65 (45.8)	57 (51.4)	22 (61.1)	0.271
0–1	193 (51.6)	48 (56.5)	77 (54.2)	54 (48.6)	14 (38.9)	
2–4						
Abbreviations: COPD, chronic obstructive pulmonary disease; PB-FEV ₁ , post-bronchodilator forced expiratory volume in one second;						
mMRC, modified Medical Research Council; SD, standard deviation; CI, confidence interval.						

PB-FEV₁, COPD exacerbation, and dyspnea symptom

The frequency of all and moderate COPD exacerbations was significantly different across the patient groups with different severity of airflow limitation based on PB-FEV₁ (both p values < 0.001). Patients with PB-FEV₁ < 30% predicted had significantly more frequent exacerbation of all types than those with PB-FEV₁ 30–49% predicted (4.0 ± 7.0 versus 1.8 ± 2.9, p < 0.001), PB-FEV₁ 50–79% predicted (4.0 ± 7.0 versus 1.6 ± 2.7, p < 0.001), and PB-FEV₁ ≥ 80% predicted (4.0 ± 7.0 versus 1.1 ± 1.8, p = 0.002). Moderate exacerbations were also significantly more frequent in patients with PB-FEV₁ < 30% predicted than that of patients with PB-FEV₁ 30–49% predicted (3.0 ± 5.5 versus 1.0 ± 1.8, p < 0.001), PB-FEV₁ 50–79% predicted (3.0 ± 5.5 versus 1.0 ± 1.8, p < 0.001) and PB-FEV₁ ≥ 80% predicted (3.0 ± 5.5 versus 0.7 ± 1.1, p = 0.001). When compared between the COPD patients with PB-FEV₁ 30–49% predicted, PB-FEV₁ 50–79% predicted,

and PB-FEV₁ ≥ 80% predicted, there was no significant difference in the frequency of all (p = 0.851–0.984) and moderate exacerbation (p = 0.970–0.999).

Even though patients with more severe airflow limitation had more frequent severe exacerbations, the difference was not significant (p = 0.106). Similarly, a higher percentage of patients with more severe airflow limitation were more symptomatic from dyspnea (mMRC 2–4) but the difference across the patient groups was also not significant (p = 0.271).

PB-FEV₁ and HRQOL

The patients' CAT and SGRQ-c scores were higher than normal regardless of their PB-FEV₁ (Table 2). Patients with more severe airflow limitation based on their PB-FEV₁ had higher total scores of CAT and SGRQ-c compared to those with less severe airflow limitation but the difference was not statistically significant (p = 0.230, and p = 0.121, respectively).

Table 2

CAT and SGRQ-c score of COPD patients according to the severity of airflow limitation based on PB-FEV₁

HRQOL parameters	All patients	Severity of airflow limitation based on PB-FEV ₁ (% predicted)				p-value
		< 30%	30–49%	50–79%	≥ 80%	
CAT score, (means ± SD, 95% CI)	14.8 ± 10.1; 13.8–15.8	15.7 ± 11.1; 13.3–18.1	14.9 ± 10.1; 13.2–16.5	15.1 ± 9.9; 13.2–17.0	11.6 ± 8.1; 8.9–14.4	0.230
Total						
SGRQ-c score, % (means ± SD, 95% CI)	40.4 ± 26.0; 37.8–43.1	43.6 ± 29.2; 37.3–49.9	41.3 ± 27.1; 36.8–45.8	39.8 ± 23.7; 35.4–44.3	31.4 ± 18.5; 25.1–37.7	0.121
Total	42.7 ± 26.4; 40.0–45.3	47.0 ± 29.2; 40.7–53.3	44.1 ± 27.8; 39.5–48.8	41.1 ± 22.7; 36.8–45.4	31.8 ± 21.4; 24.6–39.1	0.087
Symptoms	48.6 ± 30.4; 45.5–51.7					0.192
Activities		53.8 ± 32.5; 46.8–60.8	50.4 ± 32.1; 45.0–55.7	44.5 ± 27.2; 39.4–49.7	42.2 ± 26.1; 33.3–51.0	
Impact	34.8 ± 29.4; 31.8–37.8					
		36.5 ± 32.9; 29.4–43.6	34.9 ± 29.2; 30.1–39.8	36.6 ± 28.8; 31.2–42.0	25.0 ± 21.5; 17.7–32.2	

Abbreviations: HRQOL, health-related quality of life; CAT, COPD Assessment Tool; SGRQ-c, St George's Respiratory Questionnaire for COPD; COPD, chronic obstructive pulmonary disease; PB-FEV₁, post-bronchodilator forced expiratory volume in one second; SD, standard deviation; CI, confidence interval.

There was no significant difference in the scores of each of the SGRQ-c components (except symptoms, p = 0.026) according to the severity of airflow limitation based on PB-FEV₁. For the symptoms

component, patients with PB-FEV₁ < 30% predicted had a significantly higher score than those with PB-FEV₁ ≥ 80% predicted (47.0 ± 29.2 versus 31.8 ± 21.4, p = 0.020).

Correlation and regression of PB-FEV₁, COPD exacerbation frequency, dyspnea symptom, and HRQOL

There were weak negative correlations between PB-FEV₁ and exacerbation frequency (r = - 0.182, p < 0.001), mMRC score (r = - 0.121, p = 0.020), and SGRQ-c score (r = - 0.114, p = 0.028), respectively (Table 3). There was no correlation between PB-FEV₁ and CAT score (r = - 0.072, p = 0.162). Exacerbation frequency was positively correlated to the mMRC, CAT, and SGRQ-c scores, respectively with moderate coefficient (r = 0.407–0.482, all p < 0.001). There were strong positive correlations between mMRC score and CAT score (r = 0.727) and SGRQ-c score (r = 0.847), respectively while CAT score was strongly correlated to SGRQ-c score (r = 0.851) (all p < 0.001).

Table 3

Pearson correlation of PB-FEV₁ with COPD exacerbation frequency and scores of mMRC, CAT, and SGRQ-c, respectively

Variables	N	r	p-value
PB-FEV ₁ % with exacerbation	374	- 0.183	< 0.001
PB-FEV ₁ % with mMRC	374	- 0.121	0.020
PB-FEV ₁ % with CAT	374	- 0.072	0.162
PB-FEV ₁ % with SGRQ-c	374	- 0.114	0.028
Exacerbation with mMRC	374	0.407	< 0.001
Exacerbation with CAT	374	0.445	< 0.001
Exacerbation with SGRQ-c	374	0.482	< 0.001
mMRC with CAT	374	0.727	< 0.001
mMRC with SGRQ-c	374	0.847	< 0.001
CAT with SGRQ-c	374	0.851	< 0.001
Abbreviations: PB-FEV ₁ , post-bronchodilator forced expiratory volume in one second; mMRC, modified Medical Research Council; CAT, COPD Assessment Tool; SGRQ-c, St George's Respiratory Questionnaire for COPD; COPD, chronic obstructive pulmonary disease; r, co-efficient.			

For linear regression, exacerbation frequency equals to 3.870–0.036(PB-FEV₁ %) (R^2 = 0.033) (beta = - 0.183); mMRC equals to 2.085–0.007(PB-FEV₁ %) (R^2 = 0.015) (beta = - 0.121); CAT equals to 16.439–0.035(PB-FEV₁ %) (R^2 = 0.015) (beta = - 0.072); and SGRQ-c equals to 47.049–0.139(PB-FEV₁ %) (R^2 =

0.013) (beta = - 0.114). Other linear regressions involving exacerbation frequency, mMRC, CAT, and SGRQ-c are as shown in Table 4.

Table 4
Linear regression between COPD exacerbation frequency and scores of mMRC, CAT, and SGRQ-c, respectively

Variables	<i>R</i>	<i>R</i> ²	Constant	B	SE	beta	t	p-value
PB-FEV ₁ % and exacerbation	0.183	0.033	3.870	-0.036	0.010	-0.183	-3.588	< 0.001
PB-FEV ₁ % and mMRC	0.121	0.015	2.085	-0.007	0.003	-0.121	-2.344	0.020
PB-FEV ₁ % and CAT	0.072	0.005	16.439	-0.035	0.025	-0.072	-1.401	0.162
PB-FEV ₁ % and SGRQ-c	0.114	0.013	47.049	-0.139	0.063	-0.114	-2.204	0.028
Exacerbation and mMRC	0.407	0.165	1.478	0.123	0.014	0.407	8.587	< 0.001
Exacerbation and CAT	0.445	0.198	12.480	1.075	0.112	0.445	9.573	< 0.001
Exacerbation and SGRQ-c	0.482	0.233	33.968	2.999	0.282	0.482	10.619	< 0.001
mMRC and CAT	0.727	0.529	4.656	5.819	0.285	0.727	20.436	< 0.001
mMRC and SGRQ-c	0.847	0.717	10.062	17.425	0.568	0.847	30.676	< 0.001
CAT – SGRQ-c	0.851	0.724	8.039	2.189	0.070	0.851	31.251	< 0.001
Abbreviations: mMRC, modified Medical Research Council; CAT, COPD Assessment Tool; SGRQ-c, St George's Respiratory Questionnaire for COPD; COPD, chronic obstructive pulmonary disease; B, unstandardized beta; SE, standard error.								

Discussion

In this analysis, the majority (60.7%) of the COPD patients had severe or very severe airflow limitation. Biomass smoke exposure was significantly more common among patients with very severe airflow limitation. Similarly, all and moderate COPD exacerbations were significantly more frequent in those with very severe airflow limitation. Regardless of airflow limitation severity, the HRQOL of the patients was markedly impaired compared to healthy individuals. Even though patients with more severe airflow limitation had more frequent severe exacerbations, higher dyspnea symptom score, and poorer HRQOL,

these were not significantly different across the severity of airflow limitation groups. Patients with mild airflow limitation had fewer respiratory symptoms than those with very severe airflow limitation. PB-FEV₁ was only weakly associated with exacerbation frequency, dyspnea symptom, and HRQOL; exacerbation frequency was moderately correlated with dyspnea symptom and HRQOL; while dyspnea symptom was strongly correlated with HRQOL.

In the Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) study, COPD exacerbations were more frequent and more severe as the severity of airflow limitation increased. (17) The COPD in Five Latin American Cities (PLATINO), and COPD and Systemic Consequences-Comorbidities Network (COSYCONET) reported significantly more frequent exacerbations among patients with severe to very severe airflow limitation.(21, 22) In the Study to Understand Mortality and Morbidity in COPD (SUMMIT), COPD patients in the lowest quantiles (FEV₁ < 53.5% predicted) of airflow limitation reported a significantly higher risk of moderate-to-severe and severe exacerbations.(23) The Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) study and a systemic review by Westwood et al reported an inverse relationship between exacerbation and FEV₁ but the correlation was small ($r = -0.12$, $p < 0.0001$; and $r = -0.27$, $p = 0.049$, respectively).(24, 25) The findings of significantly more frequent exacerbations in our patients with very severe airflow limitation and a small correlation with PB-FEV₁ are consistent with the findings of these studies.

With regard to associations between FEV₁ and dyspnea symptom, Oga et al reported a medium correlation ($r = -0.37$, $p < 0.05$),(26) Huang et al reported a small correlation ($r = -0.234$, $p < 0.001$),(27) while the post-hoc analysis of the Effect of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-Dose Combination on Symptoms and Health Status in Patients with Moderate COPD (CRYSTAL) study did not show any correlation ($r = 0.121$).(28) This analysis showed a small correlation between PB-FEV₁ and dyspnea symptom which is only similar to that reported by Huang et al.(27)

Unlike the present study, Izquierdo et al and Hong et al reported that HRQOL was significantly different between patients with different COPD severity.(29, 30) The Clinical COPD Questionnaire (CCQ) was used in the former study while the European Quality of Life Five Dimensions (EQ-5D) was used in the latter. Meanwhile, Agrawal et al and Balcells et al reported a significantly poorer HRQOL assessed by SGRQ-c in patients with stage III /IV and stage IV COPD, respectively.(31, 32) For the association between FEV₁ and HRQOL, Ahmed et al,(33) Burgel et al,(34) and Zamzam et al (35) reported a large correlation (SGRQ-c, $r = -0.86$, $p < 0.001$; SGRQ-c, $r = -0.56$, $p < 0.001$; and $r = -0.65$, $p < 0.001$, respectively); while Deslee et al,(36) Oga et al,(26) and Westwood et al (25) (SGRQ-c, $r = -0.372$, $p < 0.0001$; $r = -0.44$, $p = 0.007$; and $r = -0.46$, $p < 0.001$, respectively), as well as Kim et al (CCQ, $r = -0.35$; and EQ-5D, $r = 0.30$) and Garrido et al (12-Item Short Form Survey: physical component, $r = 0.38$, $p < 0.001$) reported a medium correlation.(37, 38) Sundh et al and Bentsen et al reported a small correlation between FEV₁ and HRQOL (CAT, $r = -0.13$, $p = 0.001$; and EQ-5D, $r = 0.008$, $p < 0.0001$ and 36-Item Short Form Survey: physical, $r = 0.19$, $p = 0.007$; mental, $r = -0.14$, $p = 0.043$, respectively),(39, 40) which were similar to our findings.

Studies have shown patients with frequent COPD exacerbations have significantly worse dyspnea symptom and HRQOL.(6, 41) Our analysis shows a medium correlation between exacerbation frequency and dyspnea symptom as well as HRQOL, consistent with that reported by Kelly et al (mMRC, $r = 0.31$; and CAT, $r = 0.42$, both $p < 0.0001$),(42) Burgel et al (SGRQ-c, $r = 0.31$, $p < 0.001$),(34) and Deslee et al (SGRQ-c, $r = 0.391$, $p < 0.0001$).(36) To date, a strong correlation between mMRC and HRQOL has been reported by the majority of the studies including that by Deslee et al (SGRQ-c, $r = 0.602$, $p < 0.0001$),(36) Ahmed et al (SGRQ-c, $r = 0.59$, $p < 0.001$),(33) Burgel et al, (SGRQ-c, $r = 0.53$, $p < 0.01$),(34) and Kelly et al (CAT, $r = 0.50$, $p < 0.0001$).(42) The present study and another study in Japan by Horita et al (CAT, $r = 0.88$, $p < 0.001$) show a very large correlation between mMRC and HRQOL.(43)

FEV₁ is a unidimensional measurement that reflects the pathophysiology of COPD while exacerbation, dyspnea symptom, and HRQOL are multidimensional measurements of COPD consequences from the patients' perspective.(44) This explains the absence or small correlation between FEV₁ with exacerbation, dyspnea symptom, and HRQOL. The interaction between smoking, air pollution, respiratory tract infection, bronchiectasis, blood eosinophil count, the severity of airflow limitation, prior exacerbation, and comorbidities leads to the occurrence of COPD exacerbation.(45) For dyspnea symptom, the mechanisms encompass the interaction of physiological, psychological, and emotional factors of COPD patients.(46) Meanwhile, the HRQOL of COPD patients depends on the interaction of their physical, functional, emotional, social, and economic well-being.(47) The moderate correlation between COPD exacerbation and dyspnea symptom or HRQOL is attributed to the partial overlap between their dimensions. On the other hand, most of the dimensions are overlapped between dyspnea symptom and HRQOL which explains the large correlation. Even though symptoms such as cough, sputum, and wheezing are also assessed, the majority of questions in CAT (CAT 3 – CAT 8) and SGRQ-c (part of symptoms component, most of activity and impact component) still assess dyspnea symptom or their complications as the main outcomes.(18, 19)

The findings from this study suggest that FEV₁ is not a reliable parameter to measure during the follow-up of COPD patients due to its weak correlation with exacerbation, dyspnea symptom, and HRQOL. Exacerbation should be routinely assessed as it is the prognosis hallmark of COPD and is only moderately reflected by the dyspnea symptom or HRQOL. Dyspnea symptom strongly predicts the value of HRQOL. Therefore, during a busy clinic, a simpler and time-saving tool such as mMRC should precede CAT and SGRQ-c. In short, exacerbation and mMRC are the recommended parameters to evaluate during the follow-up of COPD patients. This is in line with the Global Initiative for Chronic Obstructive Lung Disease guidelines that recommend grouping of COPD patients based on exacerbation frequency in the past one year and mMRC or CAT score at diagnosis and evaluating exacerbation and dyspnea symptom during follow-up visits.(1) Only in selected circumstances, spirometry is used to identify alternative diagnoses, suitability for interventional procedures, and to detect a rapid decline in FEV₁.

This study evaluates the core parameters of COPD simultaneously, namely FEV₁, exacerbation, dyspnea symptom, and HRQOL. Even though studies looking at these parameters have been conducted in other

parts of the world, this is one of the very few studies in the South-East Asia region. Data from different regions of the world is needed for various reasons. First, the etiology of COPD can be different. In the present study, biomass smoke exposure was reported in more than one-third of the patients. Even though FEV₁ decline due to biomass smoke exposure is slower,(48) biomass smoke exposure and cigarette smoking have an additive adverse effect on airflow obstruction.(49) Second, genetic heterogeneity can affect the presentation and outcomes of COPD. This study included the population from Peninsular Malaysia and the Island of Borneo. Third, the culture and economic activity of the population could have an impact on the perceived symptom and HRQOL. Other strengths of this study include representative sample was obtained from both the primary and tertiary care centers, as well as a similar methodology was used in both studies, therefore, minimizing any data bias. However, there are several limitations to this study. First, this was a cross-sectional study. HRQOL may vary over time and such variation may not be reflected in a cross-sectional study. Serial changes of FEV₁ may give a better understanding of the exacerbation, dyspnea symptom, and HRQOL. Second, the inclusion criteria of the studies were slightly different in terms of age and definition of fixed airway obstruction. The use of PB-FVC₆ in the second study potentially excludes a proportion of patients with mild COPD. Third, the study outcome was decided later in this post-hoc analysis. However, this study fulfilled the minimum sample size of 208 patients as calculated. Fourth, recall errors in exacerbation frequency cannot be discounted but minimized by counter checks with the medical records and family members. Fifth, the result of this study is only novel for South-East Asia. A future study that prospectively evaluates the FEV₁, exacerbation, dyspnea symptom and HRQOL of COPD patients is expected to mitigate these limitations.

Conclusions

We conclude that different severity of airflow limitation based on PB-FEV₁ was not associated with significant differences in the dyspnea symptom and HRQOL of COPD patients. Exacerbation was significantly more frequent in patients with very severe airflow limitation only. The correlation between the severity of airflow limitation with exacerbation, dyspnea symptom, and HRQOL was weak. Therefore, PB-FEV₁ measurement during the routine clinic follow-up of COPD patients does not provide additional information on top of dyspnea symptom or CAT scores and exacerbation history that may influence treatment decisions.

Abbreviations

COPD, chronic obstructive pulmonary disease; FEV₁, forced expiratory volume in one second; mMRC, modified Medical Research Council; CAT, COPD Assessment Tool; HRQOL, health-related quality of life; SGRQ-c, St George's Respiratory Questionnaire for COPD; PB-FEV₁, post-bronchodilator FEV₁; UMMC, University Malaya Medical Center; PB-FVC, post-bronchodilator forced vital capacity; PB-FVC₆, PB-FVC in six seconds; SD, standard deviation; r, correlation coefficient; ECLIPSE, Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points; PLATINO, COPD in Five Latin American Cities; COSYCONET, COPD and Systemic Consequences-Comorbidities Network; SUMMIT, Study to Understand Mortality and

Morbidity in COPD; UPLIFT, Understanding Potential Long-term Impacts on Function with Tiotropium; CRYSTAL, Effect of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-Dose Combination on Symptoms and Health Status in Patients with Moderate COPD; CCQ, Clinical COPD Questionnaire; EQ-5D, European Quality of Life Five Dimensions; CI, confidence interval; B, unstandardized beta; SE, standard error.

Declarations

Ethics Approval and Informed Consent:

The ethics approval for this study was obtained from the Medical Research and Ethics Committee of UMMC (MECID. No 2017814-5496) and the Ministry of Health Malaysia (KKM.NIHSEC/P18-27(5)). This study was also registered with the National Medical Research Register (NMRR-17-2549-38621). Written informed consent was obtained from every patient.

Consent for publication:

Not applicable.

Availability of Data and Materials:

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing Interest:

The authors declare no potential conflicts of interest in respect to the research, authorship, and publication of this article.

Funding:

This study was fully supported by the Research Acculturation Grant Scheme of the Ministry of Higher Education, Malaysia (RAGS/1/2015/SKK02/UNIMAS/03/2 or FA052000-0708-0029). The funding body only financially supported this study and did not take part in the design of the study; or collection, analysis, and interpretation of the data; or writing of the manuscript.

Authors Contributions:

CSC, DLCN, MABI, SBT, YKP and CKL contributed to the conception and design of the study; CSC, DLCN, SBM contributed to the data acquisition; CSC, DLCN, SBM, and SBT contributed to the data analysis and interpretation; CSC, DLCN, MABI, SBT, YKP and CKL contributed to the drafting of the article and critically revising it. All authors made final approval of the version to be published. All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of the work are appropriately investigated and resolved.

Acknowledgments:

We would like to thank the Director General of Health Malaysia for his permission to publish this article. We want to express our gratitude to all the patients who had participated in the study.

References

1. GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020 [Available from: <https://goldcopd.org/>].
2. Blanco I, Diego I, Bueno P, Casas-Maldonado F, Miravittles M. Geographic distribution of COPD prevalence in the world displayed by Geographic Information System maps. *European Respiratory Journal*. 2019;54(1):1900610.
3. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet Respiratory medicine*. 2017;5(9):691-706.
4. Kakavas S, Kotsiou OS, Perlikos F, Mermiri M, Mavrovounis G,ourgoulialis K, et al. Pulmonary function testing in COPD: looking beyond the curtain of FEV1. *npj Primary Care Respiratory Medicine*. 2021;31(1):23.
5. Donohue JF. Minimal clinically important differences in COPD lung function. *Copd*. 2005;2(1):111-24.
6. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. *American journal of respiratory and critical care medicine*. 1998;157(5 Pt 1):1418-22.
7. Anzueto A. Impact of exacerbations on COPD. *European Respiratory Review*. 2010;19(116):113-8.
8. O'Donnell DE, Milne KM, James MD, de Torres JP, Neder JA. Dyspnea in COPD: New Mechanistic Insights and Management Implications. *Advances in Therapy*. 2020;37(1):41-60.
9. Fayers PM, D M. *Quality of life The assessment, analysis and interpretation of patient-reported outcomes*. 2nd edition. John Wiley & Sons Ltda: West Sussex 2007.
10. Hu J, Meek P. Health-related quality of life in individuals with chronic obstructive pulmonary disease. *Heart Lung*. 2005;34(6):415-22.
11. Domingo-Salvany A, Lamarca R, Ferrer M, Garcia-Aymerich J, Alonso J, Felez M, et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. *American journal of respiratory and critical care medicine*. 2002;166(5):680-5.
12. Chai C-S, Liam C-K, Pang Y-K, Ng DL-C, Tan S-B, Wong T-S, et al. Clinical phenotypes of COPD and health-related quality of life: a cross-sectional study. *International journal of chronic obstructive pulmonary disease*. 2019;14:565-73.
13. Chai C-S, Mos SB, Ng D-L-C, Goh G-M-K-C, Su A-T, Ibrahim MAB, et al. Clinical phenotypes and health-related quality of life of COPD patients in a rural setting in Malaysia – a cross-sectional study. *BMC*

Pulmonary Medicine. 2020;20(1):254.

14. Cigarette smoking among adults and trends in smoking cessation - United States, 2008. MMWR Morbidity and mortality weekly report. 2009;58(44):1227-32.
15. Montes de Oca M, Zabert G, Moreno D, Laucho-Contreras ME, Lopez Varela MV, Surmont F. Smoke, Biomass Exposure, and COPD Risk in the Primary Care Setting: The PUMA Study. Respiratory care. 2017;62(8):1058-66.
16. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. The European respiratory journal Supplement. 2003;41:46s-53s.
17. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. The New England journal of medicine. 2010;363(12):1128-38.
18. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. The European respiratory journal. 2009;34(3):648-54.
19. Meguro M, Barley EA, Spencer S, Jones PW. Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire. Chest. 2007;132(2):456-63.
20. Ferrer M, Villasante C, Alonso J, Sobradillo V, Gabriel R, Vilagut G, et al. Interpretation of quality of life scores from the St George's Respiratory Questionnaire. The European respiratory journal. 2002;19(3):405-13.
21. Montes de Oca M, Tálamo C, Halbert RJ, Perez-Padilla R, Lopez MV, Muiño A, et al. Frequency of self-reported COPD exacerbation and airflow obstruction in five Latin American cities: the Proyecto Latinoamericano de Investigacion en Obstruccion Pulmonar (PLATINO) study. Chest. 2009;136(1):71-8.
22. Lutter JI, Jörres RA, Kahnert K, Schwarzkopf L, Studnicka M, Karrasch S, et al. Health-related quality of life associates with change in FEV(1) in COPD: results from the COSYCONET cohort. BMC Pulm Med. 2020;20(1):148.
23. Bikov A, Lange P, Anderson JA, Brook RD, Calverley PMA, Celli BR, et al. FEV(1) is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease. International journal of chronic obstructive pulmonary disease. 2020;15:1135-42.
24. Halpin DM, Decramer M, Celli B, Kesten S, Liu D, Tashkin DP. Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:653-61.
25. Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun-Niggli G, Worthy G. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res. 2011;12(1):40.
26. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. Longitudinal deteriorations in patient reported outcomes in patients with COPD. Respiratory medicine. 2007;101(1):146-53.
27. Huang W-C, Wu M-F, Chen H-C, Hsu J-Y, The Tsg. Features of COPD patients by comparing CAT with mMRC: a retrospective, cross-sectional study. npj Primary Care Respiratory Medicine. 2015;25(1):15063.

28. Kostikas K, Greulich T, Mackay AJ, Lossi NS, Aalamian-Mattheis M, Nunez X, et al. Treatment response in COPD: does FEV(1) say it all? A post hoc analysis of the CRYSTAL study. *ERJ Open Res.* 2019;5(1).
29. Izquierdo JL, Barcina C, Jiménez J, Muñoz M, Leal M. Study of the burden on patients with chronic obstructive pulmonary disease. *International Journal of Clinical Practice.* 2009;63(1):87-97.
30. Hong JY, Kim SY, Chung KS, Kim EY, Jung JY, Park MS, et al. Factors associated with the quality of life of Korean COPD patients as measured by the EQ-5D. *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation.* 2015;24(10):2549-58.
31. Agrawal SR, Joshi R, Jain A. Correlation of severity of chronic obstructive pulmonary disease with health-related quality of life and six-minute walk test in a rural hospital of central India. *Lung India.* 2015;32(3):233-40.
32. Balcells E, Gea J, Ferrer J, Serra I, Orozco-Levi M, de Batlle J, et al. Factors affecting the relationship between psychological status and quality of life in COPD patients. *Health and Quality of Life Outcomes.* 2010;8(1):108.
33. Ahmed MS, Neyaz A, Aslami AN. Health-related quality of life of chronic obstructive pulmonary disease patients: Results from a community based cross-sectional study in Aligarh, Uttar Pradesh, India. *Lung India.* 2016;33(2):148-53.
34. Burgel PR, Escamilla R, Perez T, Carré P, Caillaud D, Chanez P, et al. Impact of comorbidities on COPD-specific health-related quality of life. *Respiratory medicine.* 2013;107(2):233-41.
35. Zamzam MA, Azab NY, El Wahsh RA, Ragab AZ, Allam EM. Quality of life in COPD patients. *Egyptian Journal of Chest Diseases and Tuberculosis.* 2012;61(4):281-9.
36. Deslee G, Burgel P-R, Escamilla R, Chanez P, Court-Fortune I, Nesme-Meyer P, et al. Impact of current cough on health-related quality of life in patients with COPD. *International journal of chronic obstructive pulmonary disease.* 2016;11:2091-7.
37. Kim S-H, Oh YM, Jo M-W. Health-related quality of life in chronic obstructive pulmonary disease patients in Korea. *Health and Quality of Life Outcomes.* 2014;12(1):57.
38. Carrasco Garrido P, de Miguel Díez J, Rejas Gutiérrez J, Centeno AM, Gobartt Vázquez E, Gil de Miguel A, et al. Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study. *Health and quality of life outcomes.* 2006;4:31-.
39. Sundh J, Johansson G, Larsson K, Lindén A, Löfdahl CG, Janson C, et al. Comorbidity and health-related quality of life in patients with severe chronic obstructive pulmonary disease attending Swedish secondary care units. *Int J Chron Obstruct Pulmon Dis.* 2015;10:173-83.
40. Bentsen SB, Henriksen AH, Wentzel-Larsen T, Hanestad BR, Wahl AK. What determines subjective health status in patients with chronic obstructive pulmonary disease: importance of symptoms in subjective health status of COPD patients. *Health Qual Life Outcomes.* 2008;6:115.
41. Cheng Y, Tu X, Pan L, Lu S, Xing M, Li L, et al. Clinical characteristics of chronic bronchitic, emphysematous and ACOS phenotypes in COPD patients with frequent exacerbations. *Int J Chron Obstruct Pulmon Dis.* 2017;12:2069-74.

42. Kelly JL, Bamsey O, Smith C, Lord VM, Shrikrishna D, Jones PW, et al. Health status assessment in routine clinical practice: the chronic obstructive pulmonary disease assessment test score in outpatients. *Respiration*. 2012;84(3):193-9.
43. Horita N, Yomota M, Sasaki M, Morita S, Shinkai M, Ishigatsubo Y, et al. Evaluation of the chronic obstructive pulmonary disease assessment test in Japanese outpatients. *The clinical respiratory journal*. 2014;8(2):213-9.
44. Ghobadi H, Ahari SS, Kameli A, Lari SM. The Relationship between COPD Assessment Test (CAT) Scores and Severity of Airflow Obstruction in Stable COPD Patients. *Tanaffos*. 2012;11(2):22-6.
45. Viniol C, Vogelmeier CF. Exacerbations of COPD. *European Respiratory Review*. 2018;27(147):170103.
46. Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. *American journal of respiratory and critical care medicine*. 2012;185(4):435-52.
47. Paap MCS, Bode C, Lenferink LIM, Groen LC, Terwee CB, Ahmed S, et al. Identifying key domains of health-related quality of life for patients with Chronic Obstructive Pulmonary Disease: the patient perspective. *Health and Quality of Life Outcomes*. 2014;12(1):106.
48. Ramírez-Venegas A, Sansores RH, Quintana-Carrillo RH, Velázquez-Uncal M, Hernandez-Zenteno RJ, Sánchez-Romero C, et al. FEV1 Decline in Patients with Chronic Obstructive Pulmonary Disease Associated with Biomass Exposure. *American journal of respiratory and critical care medicine*. 2014;190(9):996-1002.
49. Kurmi OP, Devereux GS, Smith WCS, Semple S, Steiner MFC, Simkhada P, et al. Reduced lung function due to biomass smoke exposure in young adults in rural Nepal. *European Respiratory Journal*. 2013;41(1):25.

Figures

Figure 1

Algorithm of patients' recruitment in the study